Fig. 4: In vivo combination of BI 894999 with CCS1477.
From: Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic
Upper row: Average tumour volumes (n = 10) ±SEM of three NC xenograft models (Ty-82: BRD4-NUT; 10–15: BRD4-NUT; 10326: BRD3-NUT). Middle row: Tumour volume of single mice (and average) at the end of the experiment. Lower row: Median body weight changes. Grey: vehicle control; green: 2 mg/kg BI 894999qd; blue: 10 mg/kg CCS1477 qd; magenta: 10 mg/kg CCS1477 qd; turquoise: combi 2 mg/kg BI 894999 and 10 mg/kg CCS1477; brown: combi 2 mg/kg BI 894999 and 5 mg/kg CCS1477 qd. One-sided non-parametric Mann–Whitney–Wilcoxon U-tests were applied to compare all treatment groups with the control, as well as the combination therapy group with the corresponding monotherapy groups. p-values were adjusted for multiple comparisons according to Bonferroni–Holm (details see Supplement Fig. 8).
